Chemical geneticsbased target identification in drug discovery

Annual Review of Pharmacology and Toxicology

Volumn 52, Issue , 2012, Pages 57-78

  Cong, Feng ^a   Cheung, Atwood K ^a   Huang, Shih Min A ^a,b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Sanofi US   (United States)

Author keywords

Cell based screen; Chemical proteomics; HIP HOP; Target deconvolution

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [N (7 BROMO 3,4 DIHYDRO 2 METHYL 4 OXO 6 QUINAZOLINYLMETHYL) N (2 PROPYNYL)AMINO] N (3 PYRIDYLMETHYL)BENZAMIDE; ANTIFUNGAL AGENT; ASCIDIDEMIN; AURILIDE; CYTOTOXIC AGENT; DASATINIB; DIAZONAMIDE A; ENZYME INHIBITOR; EXPORTIN 1; FLUCONAZOLE; FLUOROURACIL; IMATINIB; INDISULAM; KETOCONAZOLE; METHOTREXATE; NATURAL PRODUCT; NILOTINIB; ORANTINIB; RAPAMYCIN; ROMIDEPSIN; ROSCOVITINE; SORAPHEN; TACROLIMUS; TRANSCRIPTION FACTOR FKHR; TUNICAMYCIN; UNCLASSIFIED DRUG; VORINOSTAT; XAV 939;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL GENETICS; DRUG BINDING; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG TARGETING; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; STRUCTURE ACTIVITY RELATION; TARGET DECONVOLUTION; TRANSCRIPTIONAL PROFILING; VALIDATION STUDY; ANIMAL; BIOLOGY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; GENE EXPRESSION PROFILING; METHODOLOGY; PHARMACOGENETICS; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; GENE EXPRESSION PROFILING; HUMANS; PHARMACOGENETICS; PHENOTYPE; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84855874154     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010611-134639     Document Type: Article

References (122)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806-11 (Pubitemid 28099681)
2. Smukste I, Stockwell BR. 2005. Advances in chemical genetics. Annu. Rev. Genomics Hum. Genet. 6:261-86 (Pubitemid 41397084)
3. Bredel M, Jacoby E. 2004. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet. 5(4):262-75 (Pubitemid 38435622)
4. Knight ZA, Shokat KM. 2007. Chemical genetics: where genetics and pharmacology meet. Cell 128(3):425-30 (Pubitemid 46198904)
5. Fishman MC, Porter JA. 2005. Pharmaceuticals: a new grammar for drug discovery. Nature 437(7058):491-93 (Pubitemid 41613538)
6. Heitman J,MovvaNR,HallMN.1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253(5022):905-9 (Pubitemid 21917235)
7. Cooper MK, Porter JA, Young KE, Beachy PA. 1998. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280(5369):1603-7 (Pubitemid 28277705)
8. Haggarty SJ, Mayer TU, Miyamoto DT, Fathi R, King RW, et al. 2000. Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. Chem. Biol. 7(4):275-86 (Pubitemid 30199616)
9. KauTR, Schroeder F, Ramaswamy S, WojciechowskiCL, Zhao JJ, et al. 2003. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4(6):463-76 (Pubitemid 38050043)
10. Bender A, Young DW, Jenkins JL, Serrano M, Mikhailov D, et al. 2007. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb. Chem. High Throughput Screen. 10(8):719-31 (Pubitemid 350099316)
11. Bender A, Mikhailov D, Glick M, Scheiber J, Davies JW, et al. 2009. Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data. J. Proteome. Res. 8(5):2575-85
12. Rix U, Superti-Furga G. 2009. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5(9):616-24
13. Sato S, Murata A, Shirakawa T, Uesugi M. 2010. Biochemical target isolation for novices: affinity-based strategies. Chem. Biol. 17(6):616-23
14. Sleno L,Emili A. 2008. Proteomicmethods for drug target discovery. Curr. Opin. Chem. Biol. 12(1):46-54
15. Cheung AK, Jain RK. 2010. Accelerating the discovery of new drug targets with chemical proteomics. IDrugs 13(12):862-68
16. HardingMW, Galat A, UehlingDE, Schreiber SL. 1989. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341(6244):758-60 (Pubitemid 19260893)
17. Liu J, Farmer JD Jr, Lane WS, Friedman J,Weissman I, Schreiber SL. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66(4):807-15 (Pubitemid 121001714)
18. Taunton J, Hassig CA, Schreiber SL. 1996. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272(5260):408-11 (Pubitemid 26138177)
19. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, et al. 2010. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6(3):238-43
20. Han X, Aslanian A, Yates JR III. 2008. Mass spectrometry for proteomics. Curr. Opin. Chem. Biol. 12(5):483-90
21. Domon B, Aebersold R. 2006. Mass spectrometry and protein analysis. Science 312(5771):212-17
22. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, et al. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1(5):376-86
23. Ross PL,Huang YN,Marchese JN, WilliamsonB, ParkerK, et al. 2004. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3(12):1154-69
24. Thompson A, Schafer J, Kuhn K, Kienle S, Schwarz J, et al. 2003. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75(8):1895-904 (Pubitemid 36438013)
25. Wiese S, Reidegeld KA, Meyer HE, Warscheid B. 2007. Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics 7(3):340-50 (Pubitemid 46293976)
26. Shiyama T, Furuya M, Yamazaki A, Terada T, Tanaka A. 2004. Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. Bioorg. Med. Chem. 12(11):2831-41 (Pubitemid 38622119)
27. Bach S, KnockaertM, Reinhardt J, Lozach O, Schmitt S, et al. 2005. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280(35):31208-19 (Pubitemid 41291858)
28. Speers AE, Cravatt BF. 2005. A tandem orthogonal proteolysis strategy for high-content chemical proteomics. J. Am. Chem. Soc. 127(28):10018-19 (Pubitemid 40995443)
29. Fauq AH, Kache R, Khan MA, Vega IE. 2006. Synthesis of acid-cleavable light isotope-coded affinity tags (ICAT-L) for potential use in proteomic expression profiling analysis. Bioconjug. Chem. 17(1):248-54 (Pubitemid 43157609)
30. Verhelst SH, Fonovic M, Bogyo M. 2007. A mild chemically cleavable linker system for functional proteomic applications. Angew. Chem. Int. Ed. Engl. 46(8):1284-86 (Pubitemid 46981376)
31. Fonovic M, Verhelst SH, Sorum MT, Bogyo M. 2007. Proteomics evaluation of chemically cleavable activity-based probes. Mol. Cell. Proteomics 6(10):1761-70 (Pubitemid 350031677)
32. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, et al. 2000. High-performance affinity beads for identifying drug receptors. Nat. Biotechnol. 18(8):877-81 (Pubitemid 30640915)
33. Kotake Y, Sagane K, Owa T,Mimori-Kiyosue Y, Shimizu H, et al. 2007. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3(9):570-75 (Pubitemid 47294394)
34. Schirle M, Heurtier MA, Kuster B. 2003. Profiling core proteomes of human cell lines by onedimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol. Cell. Proteomics 2(12):1297-305
35. Trepel J, Mollapour M, Giaccone G, Neckers L. 2010. Targeting the dynamicHSP90 complex in cancer. Nat. Rev. Cancer 10(8):537-49
36. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, et al. 2004. A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. USA 101(34):12682-87 (Pubitemid 39122083)
37. Yamamoto K, Yamazaki A, Takeuchi M, Tanaka A. 2006. A versatile method of identifying specific binding proteins on affinity resins. Anal. Biochem. 352(1):15-23
38. Sato S, Murata A, Orihara T, Shirakawa T, Suenaga K, et al. 2011. Marine natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin. Chem. Biol. 18(1):131-39
39. Choi Y, Kawazoe Y, Murakami K, Misawa H, Uesugi M. 2003. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J. Biol. Chem. 278(9):7320-24 (Pubitemid 36800734)
40. OdaY,Owa T, Sato T, BoucherB,Daniels S, et al. 2003. Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem. 75(9):2159-65 (Pubitemid 36542358)
41. Wang G, Shang L, Burgett AW, Harran PG, Wang X. 2007. Diazonamide toxins reveal an unexpected function for ornithine δ-amino transferase inmitotic cell division. Proc.Natl. Acad. Sci. USA 104(7):2068-73 (Pubitemid 46391353)
42. Ong SE, Schenone M, Margolin AA, Li X, Do K, et al. 2009. Identifying the proteins to which smallmolecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. USA 106(12):4617-22
43. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. 2007. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25(9):1035-44 (Pubitemid 47517638)
44. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, et al. 2009. Tankyrase inhibition stabilizes axin and antagonizesWnt signalling. Nature 461(7264):614-20
45. Overington JP, Al-Lazikani B, Hopkins AL. 2006. How many drug targets are there? Nat. Rev. Drug Discov. 5(12):993-96 (Pubitemid 44835126)
46. Shoemaker BA, Panchenko AR. 2007. Deciphering protein-protein interactions: Part I. Experimental techniques and databases. PLoS Comput. Biol. 3(3):e42
47. Fleischer TC, Murphy BR, Flick JS, Terry-Lorenzo RT, Gao ZH, et al. 2010. Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol. 17(6):659-64
48. Yang J, Shamji A, Matchacheep S, Schreiber SL. 2007. Identification of a small-molecule inhibitor of Class Ia PI3Ks with cell-based screening. Chem. Biol. 14(4):371-77 (Pubitemid 46617312)
49. HurW, Sun Z, Jiang T,Mason DE, Peters EC, et al. 2010. A small-molecule inducer of the antioxidant response element. Chem. Biol. 17(5):537-47
50. Brown D, Superti-Furga G. 2003. Rediscovering the sweet spot in drug discovery. Drug Discov. Today 8(23):1067-77 (Pubitemid 38124472)
51. Bantscheff M, Scholten A, Heck AJ. 2009. Revealing promiscuous drug-target interactions by chemical proteomics. Drug Discov. Today 14(21-22):1021-29
52. Agrawal M, Garg RJ, Cortes J, Quintas-Cardama A. 2010. Tyrosine kinase inhibitors: the first decade. Curr. Hematol. Malig. Rep. 5(2):70-80
53. Catapano LA,Manji HK. 2008. Kinases as drug targets in the treatment of bipolar disorder. Drug Discov. Today 13(7-8):295-302
54. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298(5600):1912-34 (Pubitemid 35425239)
55. Haystead TA. 2006. The purinome, a complex mix of drug and toxicity targets. Curr. Top. Med. Chem. 6(11):1117-27 (Pubitemid 44110924)
56. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, et al. 2003. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. USA 100(26):15434-39 (Pubitemid 38021007)
57. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, et al. 2005. Cellular targets of gefitinib. Cancer Res. 65(2):379-82
58. Rix U, Hantschel O, D̈urnberger G, Remsing Rix LL, Planyavsky M, et al. 2007. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110(12):4055-63 (Pubitemid 350248462)
59. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. 2007. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25(9):1035-44 (Pubitemid 47517638)
60. Kim YK, Chang YT. 2007. Tagged library approach facilitates forward chemical genetics. Mol. Biosyst. 3(6):392-97 (Pubitemid 46836160)
61. Kanoh N, Honda K, Simizu S, Muroi M, Osada H. 2005. Photo-cross-linked small-molecule affinity matrix for facilitating forward and reverse chemical genetics. Angew. Chem. Int. Ed. Engl. 44(23):3559-62 (Pubitemid 40831813)
62. Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, et al. 2009. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. USA 106(51):21984-89
63. Terstappen GC, Schlupen C, Raggiaschi R, Gaviraghi G. 2007. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 6(11):891-903 (Pubitemid 350042397)
64. Becker F, Murthi K, SmithC,Come J,Costa-Roldan N, et al. 2004. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem. Biol. 11(2):211-23 (Pubitemid 38300291)
65. Caligiuri M, Molz L, Liu Q, Kaplan F, Xu JP, et al. 2006. MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells. Chem. Biol. 13(7):711-22 (Pubitemid 44109806)
66. McPherson M, Yang Y, Hammond PW, Kreider BL. 2002. Drug receptor identification from multiple tissues using cellular-derived mRNA display libraries. Chem. Biol. 9(6):691-98 (Pubitemid 34653063)
67. 2+/calmodulin function. Chem. Biol. 11(10):1455-63 (Pubitemid 39351381)
68. Kim H, Deng L, Xiong X, Hunter WD, Long MC, Pirrung MC. 2007. Glyceraldehyde 3-phosphate dehydrogenase is a cellular target of the insulin mimic demethylasterriquinone B1. J. Med. Chem. 50(15):3423-26 (Pubitemid 47195450)
69. BoehmerleW, SplittgerberU, Lazarus MB,McKenzie KM, Johnston DG, et al. 2006. Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc. Natl. Acad. Sci. USA 103(48):18356-61 (Pubitemid 44871661)
70. Huang J, Zhu H, Haggarty SJ, Spring DR, Hwang H, et al. 2004. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. USA 101(47):16594-99 (Pubitemid 39557758)
71. Smith AM, Ammar R, Nislow C, Giaever G. 2010. A survey of yeast genomic assays for drug and target discovery. Pharmacol. Ther. 127(2):156-64
72. Hoon S, St. Onge RP, Giaever G, Nislow C. 2008. Yeast chemical genomics and drug discovery: an update. Trends Pharmacol. Sci. 29(10):499-504
73. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, et al. 1999. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285(5429):901-6 (Pubitemid 29381993)
74. Giaever G, Chu AM, Ni L, Connelly C, Riles L, et al. 2002. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418(6896):387-91 (Pubitemid 34826834)
75. Giaever G, Shoemaker DD, Jones TW, Liang H,Winzeler EA, et al. 1999. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21(3):278-83 (Pubitemid 29124934)
76. Giaever G, Flaherty P, Kumm J, ProctorM,Nislow C, et al. 2004. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. USA 101(3):793-98 (Pubitemid 38121037)
77. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, et al. 2004. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116(1):121-37 (Pubitemid 38156189)
78. St. Onge RP, Mani R, Oh J, Proctor M, Fung E, et al. 2007. Systematic pathway analysis using highresolution fitness profiling of combinatorial gene deletions. Nat. Genet. 39(2):199-206 (Pubitemid 46184350)
79. Hillenmeyer ME, Fung E,Wildenhain J, Pierce SE,Hoon S, et al. 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320(5874):362-65 (Pubitemid 351555656)
80. YanZ,CostanzoM,Heisler LE, Paw J,Kaper F, et al. 2008. YeastBarcoders: a chemogenomic application of a universal donor-strain collection carrying bar-code identifiers. Nat. Methods 5(8):719-25
81. Rodriguez-Suarez R, Xu D, Veillette K, Davison J, Sillaots S, et al. 2007. Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. Chem. Biol. 14(10):1163-75 (Pubitemid 47610739)
82. Xu D, Sillaots S, Davison J, HuW, Jiang B, et al. 2009. Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans. J. Biol. Chem. 284(29):19754-64
83. Jiang B, Xu D, Allocco J, Parish C, Davison J, et al. 2008. PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. Chem. Biol. 15(4):363-74 (Pubitemid 351508424)
84. Oh J, Fung E, Schlecht U, Davis RW, Giaever G, et al. 2010. Gene annotation and drug target discovery in Candida albicans with a tagged transposon mutant collection. PLoS Pathogens 6(10):e1001140
85. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, et al. 2010. The genetic landscape of a cell. Science 327(5964):425-31
86. Rine J, Hansen W, Hardeman E, Davis RW. 1983. Targeted selection of recombinant clones through gene dosage effects. Proc. Natl. Acad. Sci. USA 80(22):6750-54 (Pubitemid 14243225)
87. Launhardt H, Hinnen A, Munder T. 1998. Drug-induced phenotypes provide a tool for the functional analysis of yeast genes. Yeast 14(10):935-42 (Pubitemid 28327999)
88. Vahlensieck HF, Pridzun L, Reichenbach H, Hinnen A. 1994. Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A. Curr. Genet. 25(2):95-100 (Pubitemid 24025638)
89. Butcher RA, Schreiber SL. 2006. A microarray-based protocol for monitoring the growth of yeast overexpression strains. Nat. Protoc. 1(2):569-76
90. Ho CH, Magtanong L, Barker SL, Gresham D, Nishimura S, et al. 2009. A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. Nat. Biotechnol. 27(4):369-77
91. Jones GM, Stalker J, Humphray S, West A, Cox T, et al. 2008. A systematic library for comprehensive overexpression screens in Saccharomyces cerevisiae. Nat. Methods 5(3):239-41 (Pubitemid 351325647)
92. Hoon S, Smith AM, Wallace IM, Suresh S, Miranda M, et al. 2008. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat. Chem. Biol. 4(8):498-506
93. Pathania R, Zlitni S, Barker C, Das R, Gerritsma DA, et al. 2009. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat. Chem. Biol. 5(11):849-56
94. KemmerD,McHardy LM,Hoon S, Reberioux D, Giaever G, et al. 2009. Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis. BMC Microbiol. 9:9
95. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, et al. 2004. The status, quality, and expansion of the NIH full-length cDNA project: theMammalian Gene Collection (MGC). Genome Res. 14(10B):2121-27 (Pubitemid 39440194)
96. Baross A, Butterfield YS, Coughlin SM, Zeng T,Griffith M, et al. 2004. Systematic recovery and analysis of full-ORF human cDNA clones. Genome Res. 14(10B):2083-92 (Pubitemid 39440190)
97. Sachse C, Echeverri CJ. 2004. Oncology studies using siRNA libraries: the dawn of RNAi-based genomics. Oncogene 23(51):8384-91 (Pubitemid 39540720)
98. Butcher RA, Schreiber SL. 2005. Using genome-wide transcriptional profiling to elucidate smallmolecule mechanism. Curr. Opin. Chem. Biol. 9(1):25-30 (Pubitemid 40208621)
99. Stoughton RB, Friend SH. 2005. How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug Discov. 4(4):345-50 (Pubitemid 41130947)
100. Gunther EC, Stone DJ, Rothberg JM, Gerwien RW. 2005. A quantitative genomic expression analysis platform for multiplexed in vitro prediction of drug action. Pharmacogenomics J. 5(2):126-34 (Pubitemid 40468119)
101. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, et al. 2000. Functional discovery via a compendium of expression profiles. Cell 102(1):109-26
102. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE III. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279(38):40174-84 (Pubitemid 39258293)
103. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. 2006. The Connectivity Map: using geneexpression signatures to connect small molecules, genes, and disease. Science 313(5795):1929-35 (Pubitemid 44497995)
104. Gunther EC, Stone DJ, Gerwien RW, Bento P, Heyes MP. 2003. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc. Natl. Acad. Sci. USA 100(16):9608-13 (Pubitemid 37033975)
105. Peck D, Crawford ED, Ross KN, Stegmaier K,Golub TR, Lamb J. 2006. Amethod for high-throughput gene expression signature analysis. Genome Biol. 7(7):R61
106. StegmaierK,Wong JS, Ross KN,ChowKT, Peck D, et al. 2007. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 4(4):e122
107. Weiss WA, Taylor SS, Shokat KM. 2007. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol. 3(12):739-44 (Pubitemid 350126879)
108. Chen B, Dodge ME, Tang W, Lu J, Ma Z, et al. 2009. Small molecule-mediated disruption of Wntdependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5(2):100-7
109. Morohashi K, Yoshino A, Yoshimori A, Saito S, Tanuma S, et al. 2005. Identification of a drug target motif: an anti-tumor drug NK109 interacts with a PNxxxxP. Biochem. Pharmacol. 70(1):37-46 (Pubitemid 40797869)
110. Kuettel S, Mosimann M, Maser P, Kaiser M, Brun R, et al. 2009. Adenosine Kinase of T. b. rhodesiense identified as the putative target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine using chemical proteomics. PLoS Negl. Trop. Dis. 3(8):e506
111. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. 2002. Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA 99(22):14071-76 (Pubitemid 35257626)
112. Frank-Kamenetsky M, Zhang XM, Bottega S, Guicherit O, Wichterle H, et al. 2002. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J. Biol. 1(2):10
113. Tanaka K, Okabayashi K, Asashima M, Perrimon N, Kadowaki T. 2000. The evolutionarily conserved porcupine gene family is involved in the processing of theWnt family. Eur. J. Biochem. 267(13):4300-11 (Pubitemid 30436127)
114. Salic A, Lee E, Mayer L, Kirschner MW. 2000. Control of β-catenin stability: reconstitution of the cytoplasmic steps of theWnt pathway in Xenopus egg extracts. Mol. Cell 5(3):523-32
115. Lee E, Salic A, Kr̈uger R, Heinrich R, Kirschner MW. 2003. The roles of APC and axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol. 1(1):E10
116. Waaler J, Machon O, von Kries JP,Wilson SR, Lundenes E, et al. 2011. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res. 71(1):197-205
117. Drews J. 2000. Drug discovery: a historical perspective. Science 287(5460):1960-64 (Pubitemid 30158662)
118. CseteM. 2010. Translational prospects for human induced pluripotent stem cells. Regen. Med. 5(4):509-19
119. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, et al. 2007. Engineering tumors with 3D scaffolds. Nat. Methods 4(10):855-60 (Pubitemid 350055585)
120. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, et al. 2009. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459(7244):262-65
121. Austin CP, Brady LS, Insel TR, Collins FS. 2004. NIH Molecular Libraries Initiative. Science 306(5699):1138-39 (Pubitemid 39488980)
122. Wilk W, Zimmermann TJ, Kaiser M, Waldmann H. 2010. Principles, implementation, and application of biology-oriented synthesis (BIOS). Biol. Chem. 391(5):491-97